Pinzón Mariño Sergio, Bakali Badesa Samira, Viso Soriano María Jesús, Izquierdo Garcia Isabel
Department of Hematology and Hemotherapy.
Department of Anatomical Pathology, Hospital Universitario Miguel Servet, Spain.
Hematol Rep. 2021 Mar 12;13(1):8574. doi: 10.4081/hr.2021.8574. eCollection 2021 Mar 5.
Hemorrhagic cystitis (HC) secondary to BK polyomavirus (BKPyV) is a frequent complication related to allogenic stem cell transplantation. With an important morbidity and mortality, this disease doesn't have a stablished standard treatment or prophylaxis strategies. At this moment, the supportive therapies approved to treat included hyperhydration, forced diuresis and transfusion support. Cidofovir is a nucleotide analog of deoxycytidine monophosphate against DNA viruses and it has been described for the treatment of BKPyV-HC, but at this moment, is not a front-line therapy. We report a successful case after the use of Cidofovir without Probenecid. No adverse effect was developed under the treatment, and after 4 weeks of treatment, the patient achieved an excellent response.
BK多瘤病毒（BKPyV）继发的出血性膀胱炎（HC）是异基因干细胞移植常见的并发症。这种疾病具有较高的发病率和死亡率，目前尚无既定的标准治疗方法或预防策略。目前，批准用于治疗的支持性疗法包括水化、强制利尿和输血支持。西多福韦是一种针对DNA病毒的脱氧胞苷单磷酸核苷酸类似物，已被用于治疗BKPyV-HC，但目前并非一线治疗方法。我们报告了1例未使用丙磺舒而使用西多福韦治疗成功的病例。治疗期间未出现不良反应，治疗4周后，患者取得了良好的疗效。
